120 related articles for article (PubMed ID: 23901848)
21. Randomized controlled pilot study of B cell-targeted induction therapy in HLA sensitized kidney transplant recipients.
Ejaz NS; Shields AR; Alloway RR; Sadaka B; Girnita AL; Mogilishetty G; Cardi M; Woodle ES
Am J Transplant; 2013 Dec; 13(12):3142-54. PubMed ID: 24266968
[TBL] [Abstract][Full Text] [Related]
22. Intestine and multivisceral transplantation in the United States: a report of 20-year national registry data (1990-2009).
Cai J
Clin Transpl; 2009; ():83-101. PubMed ID: 20524278
[TBL] [Abstract][Full Text] [Related]
23. Outcome of desensitization in human leukocyte antigen- and ABO-incompatible living donor kidney transplantation: a single-center experience in more than 100 patients.
Al Meshari K; Pall A; Chaballout A; El Gamal H; Al Mana H; Humaidan H; Alzayer F; Al Talhi M
Transplant Proc; 2013 May; 45(4):1423-6. PubMed ID: 23726587
[TBL] [Abstract][Full Text] [Related]
24. Failure of bortezomib to cure acute antibody-mediated rejection in a non-compliant renal transplant patient.
Ryckewaert A; Allain-Launay E; Moreau A; Blancho G; Cesbron A; Blin N; Roussey G
Pediatr Transplant; 2013 Sep; 17(6):E131-6. PubMed ID: 23834525
[TBL] [Abstract][Full Text] [Related]
25. Kidney transplant in highly sensitized patients after desensitization with plasmapheresis and low-dose intravenous immunoglobulin.
Yuan XP; Wang CX; Gao W; Fu Q; He XS
Exp Clin Transplant; 2010 Jun; 8(2):130-5. PubMed ID: 20565369
[TBL] [Abstract][Full Text] [Related]
26. Abrogation of antibodies improves outcome of renal transplantation.
Trivedi HL; Vanikar AV; Gumber MR; Patel HV; Shah PR; Kute VB
Transplant Proc; 2012 Jan; 44(1):241-7. PubMed ID: 22310623
[TBL] [Abstract][Full Text] [Related]
27. Plasma exchange conditioning for ABO-incompatible renal transplantation.
Winters JL; Gloor JM; Pineda AA; Stegall MD; Moore SB
J Clin Apher; 2004; 19(2):79-85. PubMed ID: 15274200
[TBL] [Abstract][Full Text] [Related]
28. Outcome of renal transplants from pediatric donors <5 yr of age.
El-Sabrout R; Buch K
Clin Transplant; 2005 Jun; 19(3):316-20. PubMed ID: 15877791
[TBL] [Abstract][Full Text] [Related]
29. Kinetics of cellular and humoral immunity in a successful case of positive crossmatch kidney transplantation: a case report.
Tanimine N; Ide K; Yamashita M; Tanaka Y; Igarashi Y; Banshodani M; Tazawa H; Basnet NB; Doskali M; Onoe T; Tashiro H; Ohdan H
Transplant Proc; 2011; 43(6):2411-4. PubMed ID: 21839279
[TBL] [Abstract][Full Text] [Related]
30. Desensitizing the broadly human leukocyte antigen-sensitized patient awaiting deceased donor kidney transplantation.
Jordan SC; Reinsmoen N; Lai CH; Cao K; Kahwaji J; Peng A; Villicana R; Vo A
Transplant Proc; 2012 Jan; 44(1):60-1. PubMed ID: 22310579
[TBL] [Abstract][Full Text] [Related]
31. Analysis of anti-HLA antibodies in sensitized kidney transplant candidates subjected to desensitization with intravenous immunoglobulin and rituximab.
Lobashevsky AL; Higgins NG; Rosner KM; Mujtaba MA; Goggins WC; Taber TE
Transplantation; 2013 Jul; 96(2):182-90. PubMed ID: 23778648
[TBL] [Abstract][Full Text] [Related]
32. Targeted monitoring of donor-specific HLA antibodies following renal transplantation.
Almeshari K; Pall A; Chaballout A; Elgamal H; Almana H; Alzayer F; Abaalkhail N; Altalhi M
Clin Transpl; 2011; ():395-400. PubMed ID: 22755437
[TBL] [Abstract][Full Text] [Related]
33. Low median fluorescence intensity could be a nonsafety concept of immunologic risk evaluation in patients with shared molecular eplets in kidney transplantation.
Bosch A; Llorente S; Diaz JA; Salgado G; López M; Boix F; López-Hernández R; González-Soriano MJ; Campillo JA; Moya-Quiles MR; Perez-Lopez N; Minguela A; Jimeno L; Alvarez-López MR; Muro M
Hum Immunol; 2012 May; 73(5):522-5. PubMed ID: 22425738
[TBL] [Abstract][Full Text] [Related]
34. Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation.
Guthoff M; Schmid-Horch B; Weisel KC; Häring HU; Königsrainer A; Heyne N
Transpl Immunol; 2012 Jun; 26(4):171-5. PubMed ID: 22326708
[TBL] [Abstract][Full Text] [Related]
35. The acceptable reactive crossmatch (ARC), post-transplant monitoring, and their impact on kidney transplantation: a single center experience.
Leone JP; Bowers V; Baliga R; Sanders C; LeFor W; Becker D; Thompson D; Resto-Ruiz S; Lopez-Cepero M
Clin Transpl; 2011; ():373-9. PubMed ID: 22755434
[TBL] [Abstract][Full Text] [Related]
36. Rituximab and intravenous immune globulin for desensitization during renal transplantation.
Vo AA; Lukovsky M; Toyoda M; Wang J; Reinsmoen NL; Lai CH; Peng A; Villicana R; Jordan SC
N Engl J Med; 2008 Jul; 359(3):242-51. PubMed ID: 18635429
[TBL] [Abstract][Full Text] [Related]
37. Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody.
Hodges AM; Lyster H; McDermott A; Rice AJ; Smith JD; Rose ML; Banner NR
Transplantation; 2012 Mar; 93(6):650-6. PubMed ID: 22245878
[TBL] [Abstract][Full Text] [Related]
38. Bortezomib in the treatment of antibody-mediated rejection--a report of 3 cases.
Mai HL; Cesbron A; Brouard S; Blanchol G; Cantarovich D; Dantal J; Hourmant M; Lino M; Meurette A; Gosselin M; Abbadie O; Soulillou JP; Giral M
Clin Transpl; 2009; ():361-8. PubMed ID: 20524299
[No Abstract] [Full Text] [Related]
39. Rituximab induction therapy in highly sensitized kidney transplant recipients.
Yin H; Wan H; Hu XP; Li XB; Wang W; Liu H; Ren L; Zhang XD
Chin Med J (Engl); 2011 Jul; 124(13):1928-32. PubMed ID: 22088448
[TBL] [Abstract][Full Text] [Related]
40. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
Walsh RC; Everly JJ; Brailey P; Rike AH; Arend LJ; Mogilishetty G; Govil A; Roy-Chaudhury P; Alloway RR; Woodle ES
Transplantation; 2010 Feb; 89(3):277-84. PubMed ID: 20145517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
